JP7144755B2 - 薬剤、使用および方法 - Google Patents

薬剤、使用および方法 Download PDF

Info

Publication number
JP7144755B2
JP7144755B2 JP2019531644A JP2019531644A JP7144755B2 JP 7144755 B2 JP7144755 B2 JP 7144755B2 JP 2019531644 A JP2019531644 A JP 2019531644A JP 2019531644 A JP2019531644 A JP 2019531644A JP 7144755 B2 JP7144755 B2 JP 7144755B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504717A (ja
JP2020504717A5 (https=
Inventor
カルンキ，ペッカ
フォグ，カリナ
ビー スタヴェンハーゲン，ジェフリー
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2020504717A publication Critical patent/JP2020504717A/ja
Publication of JP2020504717A5 publication Critical patent/JP2020504717A5/ja
Application granted granted Critical
Publication of JP7144755B2 publication Critical patent/JP7144755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019531644A 2016-12-16 2017-12-14 薬剤、使用および方法 Active JP7144755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600769 2016-12-16
DKPA201600769 2016-12-16
PCT/EP2017/082749 WO2018109058A1 (en) 2016-12-16 2017-12-14 Agents, uses and methods

Publications (3)

Publication Number Publication Date
JP2020504717A JP2020504717A (ja) 2020-02-13
JP2020504717A5 JP2020504717A5 (https=) 2021-01-28
JP7144755B2 true JP7144755B2 (ja) 2022-09-30

Family

ID=61027650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531644A Active JP7144755B2 (ja) 2016-12-16 2017-12-14 薬剤、使用および方法

Country Status (8)

Country Link
US (1) US11325968B2 (https=)
EP (1) EP3555127B1 (https=)
JP (1) JP7144755B2 (https=)
CN (1) CN110072888B (https=)
BR (1) BR112018016717A2 (https=)
ES (1) ES3008133T3 (https=)
MA (1) MA47019A (https=)
WO (1) WO2018109058A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
JP7689373B2 (ja) * 2019-04-18 2025-06-06 エイシー イミューン ソシエテ アノニム 治療及び診断のための新規分子
MX2023011268A (es) * 2021-03-24 2023-12-14 Alkermes Inc Anticuerpos upar y proteínas de fusión con estos.
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2008509223A (ja) 2004-08-09 2008-03-27 エラン ファーマシューティカルズ，インコーポレイテッド シヌクレイノパシー（ｓｙｎｕｃｌｅｉｎｏｐａｔｈｉｃ）およびアミロイド生成性疾患の予防および処置
JP2013525266A (ja) 2010-02-26 2013-06-20 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1512203A (en) 1974-05-08 1978-05-24 Aspin F Rolls for use in profiling film
CA1186621A (en) 1981-08-10 1985-05-07 John L. Hendrix Fluoro immuno assay system
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988004777A1 (en) 1986-12-15 1988-06-30 Ultra Diagnostics Corporation Monomeric phthalocyanine reagents
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US4876190A (en) 1987-10-21 1989-10-24 Becton Dickinson & Company Peridinin-chlorophyll complex as fluorescent label
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
FR2624862B1 (fr) 1987-12-18 1990-06-08 Oris Ind Cryptates de terres rares, procedes d'obtention, intermediaires de synthese et application a titre de marqueurs fluorescents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2002004482A1 (en) 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
PL2361928T3 (pl) 2003-05-19 2017-09-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP2006031250A (ja) 2004-07-14 2006-02-02 Fuji Xerox Co Ltd 通信装置およびその制御方法
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
US20060205024A1 (en) 2005-03-08 2006-09-14 Sun Health Research Institute Method to diagnose and evaluate progression of Alzheimer's disease
WO2007011907A2 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
HUE043966T2 (hu) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
JP2014502356A (ja) 2010-11-24 2014-01-30 エラン ファーマシューティカルズ，インコーポレイテッド シヌクレイン病のマーカーとしての食作用活性
KR101308898B1 (ko) * 2011-02-08 2013-09-23 건국대학교 산학협력단 신규 항-α-시누클레인 단일클론항체 및 이를 이용한 ＥＬＩＳＡ 시스템
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
JP2013059866A (ja) 2011-09-12 2013-04-04 Seiko Epson Corp 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3341725B1 (en) 2015-08-25 2021-08-18 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
US10160800B2 (en) 2016-06-02 2018-12-25 Medimmune Limited Antibodies to α-synuclein and uses thereof
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN111630382A (zh) 2017-12-21 2020-09-04 H.隆德贝克有限公司 α-共核蛋白病的测定、方法和治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2008509223A (ja) 2004-08-09 2008-03-27 エラン ファーマシューティカルズ，インコーポレイテッド シヌクレイノパシー（ｓｙｎｕｃｌｅｉｎｏｐａｔｈｉｃ）およびアミロイド生成性疾患の予防および処置
JP2013525266A (ja) 2010-02-26 2013-06-20 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用

Also Published As

Publication number Publication date
CN110072888B (zh) 2023-07-18
US20200024337A1 (en) 2020-01-23
WO2018109058A1 (en) 2018-06-21
EP3555127B1 (en) 2024-12-18
MA47019A (fr) 2021-04-21
WO2018109058A9 (en) 2019-11-14
JP2020504717A (ja) 2020-02-13
ES3008133T3 (en) 2025-03-21
BR112018016717A2 (pt) 2018-12-26
EP3555127C0 (en) 2024-12-18
US11325968B2 (en) 2022-05-10
CN110072888A (zh) 2019-07-30
EP3555127A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
JP7138322B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
JP7144755B2 (ja) 薬剤、使用および方法
HK40127009A (en) Agents, uses and methods for the treatment of synucleinopathy
HK40013648B (en) Agents, uses and methods
HK40013648A (en) Agents, uses and methods
HK1254358B (en) Agents, uses and methods for the treatment of synucleinopathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220829

R150 Certificate of patent or registration of utility model

Ref document number: 7144755

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250